Skip to content
Screener

Opko Health OPK Pharmaceutical — Intangible Amortization

Other segment segments

Diagnostics
$2.53M-16.4%

Similar metrics at other companies

lululemon athletica logo
LULUAmericas — Intangible Amortization
$0
AeroVironment logo
AVAVUxs — Intangible Amortization
$4.26M
Restoration Hardware logo
RHRH — Intangible Amortization
-$30K-42.9%
Hasbro logo
HASEntertainment — Intangible Amortization
$4.2M-10.6%
TFI
TFINBanking — Intangible Amortization
$269K-30.1%
TFI
TFINFactoring — Intangible Amortization
$111K-42.5%

Other financials

Income statement

See full
Revenue$163.6M+4.3%
Gross profit$80.0M+62.0%
Operating income-$7.0M+88.4%
Net income-$8.4M+94.3%
EPS (diluted)-$0.01+94.7%

Balance sheet

See full
Cash & equivalents$40.6M-62.5%
Total debt$49.9M-7.5%
Total equity$1.2B-8.7%
Total assets$1.8B-7.3%

Cash flow

See full
Operating cash flow-$43.5M+47.9%
CapEx$3.0M-8.5%
Free cash flow-$46.5M+46.4%

Valuation

See full
Market cap$985.15M-2.3%
P/S1.7×+0.2×

Profitability

See full
Gross margin40.8%+8.1pp
Operating margin-8.2%-3.5pp
Net margin-12.4%-4.3pp
FCF margin-22.8%-6.7pp

Returns & leverage

See full
Return on equity-5.9%-2.1pp
Debt / equity0.0×
Current ratio3.3×-0.1×

Where this comes from

Reported directly by Opko Health in its filing.

Tagged under the XBRL concept us-gaap:AmortizationOfIntangibleAssets.

The source filing: Opko Health’s 10-Q, filed July 27, 2026.

Filed
Jul 27, 2026, 4:12 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-318090
(In thousands) / Revenue from services: / PharmaceuticalFor the three months ended June 30, 2026 / —For the three months ended June 30, 2025 / —For the six months ended June 30, 2026 / —For the six months ended June 30, 2025 / —
Corporate13380267145
$33,166$30,342$62,365$61,183
Amortization of intangible assets:
Pharmaceutical$16,436$16,415$32,869$32,525
Diagnostics2,5333,0295,0666,779
Corporate
$18,969$19,444$37,935$39,304
Other segment items:

Item 1. Financial Statements

FAQ

What is Opko Health's pharmaceutical — intangible amortization?
Opko Health (OPK) reported pharmaceutical — intangible amortization of $16.44M in Q2 2026.
How has Opko Health's pharmaceutical — intangible amortization changed year-over-year?
Opko Health's pharmaceutical — intangible amortization increased by 0.1% year-over-year, from $16.42M to $16.44M.
What is the long-term trend for Opko Health's pharmaceutical — intangible amortization?
Over 2 years (2023 to 2025), Opko Health's pharmaceutical — intangible amortization has grown at a -0.2% compound annual growth rate (CAGR), from $65.84M to $65.59M.
What does pharmaceutical — intangible amortization mean?
The systematic allocation of the cost of intangible assets, such as patents, licenses, and acquired technology, over their estimated useful lives within the pharmaceutical segment. This non-cash expense reflects the consumption of the segment's intellectual property value.

Ask your AI about Opko Health's pharmaceutical — intangible amortization.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude